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Abstract
Background: Obstructive sleep apnea (OSA) is prevalent in individuals with Osteogenesis imperfecta (OI). To date,
no study has investigated treatment of OSA in adult individuals with OI using positive airway pressure (PAP). This
observational pilot study examined the adherence of adults with OI to treatment of OSA with PAP therapy, and the
evolution of self-experienced sleepiness and depression symptoms before and after treatment.
Methods: We included 20 patients, with a mean age of 51 years, who represented varying severity of OI and
displayed an apnea and hypopnea index ≥ 5 /sleeping hour as recorded by an overnight polysomnography. PAP
therapy was proposed to all patients. Epworth Sleepiness Scale (ESS) questionnaire to evaluate daytime sleepiness,
and a validated self-rating depression questionnaire to identify possible depression, were completed prior to PAP
therapy and repeated after a minimum of one year. The datasets supporting the conclusions of this article are
included within the article.
Results: From the 20 patients, 15 initiated PAP therapy, and two patients later interrupted it. The mean PAP follow-
up period was 1230 days. At baseline, an abnormally high ESS score was reported by 29% of the respondents, and
an abnormally high number of symptoms suggesting depression by 29%. Follow-up questionnaires were
completed by 60% of the patients, of whom 83% were adherent to PAP treatment. ESS score and depression
symptoms did not decrease significantly with PAP therapy.
Conclusions: Patients with OI accepted well PAP therapy and remained compliant. Sleepiness and depression
persisted unaltered despite good PAP adherence. These unexpectedly poor improvements in symptoms by PAP
therapy may be due to subjective depression symptoms and the complexity of factors underlying persisting
sleepiness in OI. Further research is needed to confirm this novel finding.
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Background
Osteogenesis imperfecta (OI) is a group of rare genetic
disorders, in which mutations impair normal synthesis,
assembly, folding, posttranslational modification, secretion,
or structure of type I collagen. The succedent detriment of
collagen-rich tissues leads to typical clinical manifestations,
such as bone fragility, hyperextensibility of ligaments, short
stature, hearing impairment, and a tendency to progressive
skeletal deformity of long bones, spine and cranial base [1,
2]. Phenotypic classification of OI into five types covers a
severity range from mild non-deforming (type I) to severe
(type III) and lethal (type II) [3].
In addition to a variety of somatic changes, patients
with OI experience pain, persisting daytime sleepiness,
and fatigue [3–5]. Our previous studies indicate that one
of the factors contributing to fatigue in OI might be
sleep apnea [6, 7]. Previous studies [4, 7] have reported
in adults with OI a prevalence of sleep apnea exceeding
that in normal population [8].
In general, individuals with obstructive sleep apnea
(OSA) show a high prevalence of depression [9], and de-
pression and tiredness are highly correlated traits [10].
Treatment of OSA with positive airway pressure (PAP)
has been documented to result in subjective alleviation
of daytime sleepiness, fatigue and depression [11].
The purpose of this study was firstly, to evaluate ac-
ceptance of and adherence to positive airway pressure
(PAP) therapy among adult OI patients, and secondly, to
evaluate the effect of PAP therapy on self-experienced
daytime sleepiness and depression.
Methods
Study population
In 2015, we invited all 151 patient members, over the
age of 16 years, of the Finnish OI Society, to participate
in a study exploring the quality of sleep and its relation
to daytime well-being [6, 7]. The study protocol was ap-
proved by the Research Ethic Board of Helsinki Univer-
sity Hospital, Helsinki, Finland (12/18/2014). Informed
consent was obtained from all participants. The present
study was undertaken as a follow-up evaluation among
those enrolled in a sleep recording.
A total of 20 retained patients constituted the present
follow-up study group. Of them, 13 had been included
in an overnight polysomnography study previously, as
reported by our group in 2018 [7]. Additional 4 patients,
who had undergone a comprehensive overnight poly-
somnography in a sleep laboratory using identical
methods [7], were included in this study. The remaining
3 participants had previously undergone ambulatory
polysomnography (American Academy of Sleep Medi-
cine Type III sleep monitor), and the data were gathered
from their medical records. Total sleep time was un-
known, but at the time of the testing had been deemed
sufficient by the treating physician. The scoring guide-
lines and sleep apnea definition of the American Acad-
emy of Sleep Medicine were applied [12]. All patients
had an apnea-hypopnea index (AHI) or respiratory event
index (REI) ≥ 5 events per hour of sleep.
Positive Airway Pressure therapy (PAP)
PAP therapy was proposed to all patients, as myofunctional
therapy and oral appliance therapy are contraindicated in
this patient group frequently suffering from co-morbidities
of muscle weakness, joint laxity, and craniofacial anomalies
[4, 13, 14]. PAP therapy was initiated mainly at home with
an automatic PAP device, APAP (ResMed, Sydney,
Australia) according to a protocol previously described
[15]. PAP data was obtained from ResScan program
(ResMed, Sydney, Australia). Acceptance and adherence
were evaluated using medical records, self-reports, and data
from CPAP device.
Questionnaires
Epworth Sleepiness Scale (ESS) was employed to evalu-
ate daytime sleepiness. ESS scale ranges between 0 and
24, where a value of 11 or above signifies pathological
sleepiness [16]. A validated self-rating depression ques-
tionnaire (DEPS) was applied to identify possible depres-
sion. DEPS scale ranges between 0 and 30, where a value
of 12 or above is considered a cut-off point for clinical
depression [17].
Baseline ESS score, before treatment, was available
from 13 patients included in our previous paper [7] and
from 4 additional patients. Baseline DEPS data were
available from 11 previously reported [7] and from 3
additional patients. The self-evaluation ESS and DEPS
questionnaires were repeated in 2019 by mail after a
minimum of one year of PAP treatment.
Statistical analysis
Sample size of 20 met the recommended threshold of
12, allowing dropouts, for a sufficiently precise estimates
of mean and variance of variables with continuous out-
come in pilot studies [18]. Statistical analyses were per-
formed with SPSS version 23 software. Correlation
between the variables was examined statistically with
Spearman’s rank correlation test. Relationship between
the mean self-reported sleepiness and depression symp-
toms before and after sleep apnea treatment were com-
pared with non-parametric Mann-Whitney U test.
Results
Patient characteristics
Table 1 presents the patients’ characteristics. All the 20
patients (11 females) were ethnic Finns. The age range
was 27–77 years (mean age 51 years) at baseline prior to
treatment. The participants represented OI types I (n =
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5), III (n = 6), and IV (n = 6), as classified according to
the original Sillence classification [19]. OI type was un-
known in 3 patients. Information on the participants’ ge-
notypes was not available. Average height of the patients
was 137 cm and height Z-score ranged between − 14
and 0.1 (median − 4.5). Significant correlations were
found between severity of OI (i.e. OI type) and the
height of the individual (rs=-0.744, p < 0.001), and be-
tween the severity of OI and BMI (rs= 0.725, p < 0.001);
the more severe the OI, the shorter the individual and
the greater the BMI, as expected. Medications acting on
the central nervous system and therefore potentially in-
ducing sleepiness were used by two patients; including
opioids and anti-anxiety medication.
The average AHI/REI index had been 26 ±27 per hour
of sleep, brought about by almost entirely obstructive
apnea (obstructive AHI, known in 15 patients, averaged
23/h) (Table 1). Three patients had severe apnea and
eight had moderate apnea. The number of arousals re-
lated to the total sleep time was on average 33 with a
high deviation of ±24, implying a large variation in the
sleep fragmentation. None of the patients had severe
nocturnal hypoxemia, defined as greater than 30% cu-
mulative time spent with SpO2 below 90% (CT90) [20].
In all but one patient, the mean transcutaneous CO2 had
remained below 6.5 kPa and therefore nocturnal
hypoventilation was excluded. The augmented study
group was tested for correlations between AHI and
other variables. Again, neither the BMI or ESS score cor-
related with AHI (p > 0.05), as in our earlier report [7].
Sleep apnea treatment
According to the medical records, all of the patients had
been offered PAP therapy one to three months after the
diagnosis of OSA. One patient died before therapy initi-
ation. Three patients refused the offered therapy and
two interrupted it due to discomfort. Their treatment
interruption time point was unknown. One patient later
restarted the therapy after receiving a better suited
CPAP mask.
Effects of PAP therapy
At the follow-up time point 13 patients, 6 females and 7
males, reported using PAP therapy, as documented in
the medical reports, self-reports, and CPAP-device
downloaded data, yielding an adherence rate of 87%.
Three of them had type I OI, 4 had type III OI, 4 had
type IV OI, and 2 patients an unknown OI type. Their
average age was 54 years, and average AHI/REI before
treatment 32.9 events/hour (range 10–111). Treatment
status of one patient was unknown. Follow-up CPAP
reading, available for 6 patients, showed an average re-
sidual AHI (PAP-AHI) of 0.7 (±0.5) events/hour. Weight
measurements of these patients showed that on average
their weight had remained the same as at baseline (p =
0.79). For 11 patients, data were available regarding the
adherence rates to PAP therapy after on average of
41 months course of therapy (median 30 months, range
13–153 months) (Table 1). Information regarding adher-
ence was derived from CPAP-device downloaded data
over the whole treatment duration in half of the patients,
and from self-reports in the remaining patients whose
treatment was organized by other hospital districts. The
average usage time of PAP was 7 ±2 hours/day.
Daytime sleepiness and depression
Baseline ESS questionnaire data were available for 85%
of the patients. The total number of patients with abnor-
mally high ESS value of 11 or above, indicative of in-
creased daytime sleepiness at baseline, was 5, yielding a
29% prevalence (Fig. 1). The mean score was 7 ±4 in the
whole group, men having higher sleepiness scores (8 ±5)
than women (6 ±4) but the difference was statistically
insignificant (p = 0.536).
Baseline DEPS data, available for 70%, indicated in 4
patients (29%) a DEPS score ≥12, a cut-off value for clin-
ical depression (Fig. 1). The mean DEPS score was 9 ±7
in the whole group, and 8 ±4 for men and 10 ±9 for
women. The ESS or DEPS scores did not correlate with
each other, or with any of the other measured variables
(p > 0.05).
Follow-up ESS questionnaire was completed by 13 pa-
tients (65%), 11 of whom were using PAP (Table 1). At
the follow-up, 4 of the 13 respondents reported an ESS
score of 12 or 13 indicating excessive daytime sleepiness.
Of them, 3 were using PAP as prescribed and one had
discontinued treatment. Baseline values were available
for 3 of these 4, and they were all above the cut-off
value; ranging from 11 to 14, suggesting a persisting ex-
cessive daytime sleepiness. Two PAP-users developed
Fig. 1 Patient flow diagram
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from sleepy (ESS > 10) to not-sleepy (ESS ≤ 10), whereas
opposite change was not observed. Six patients reported
reduced ESS values with treatment and 5 an increased
value.
Mean ESS score at follow-up was 7 ±4 (Fig. 2). Among
all those 11 patients who completed the ESS question-
naire both at baseline and at follow-up, the largest ESS
value increase was 4 and the largest reduction 8, and the
median was a reduction by -1. Two patients who had de-
clined from PAP treatment showed minor changes of 1
and − 1 respectively. The mean self-reported sleepiness
as expressed by the ESS score remained unaltered with
treatment (Mann-Whitney U = 107.5, p = 0.902), and the
values showed a statistically significant positive correl-
ation between the two evaluation time points on individ-
ual level (rs=0.63, p = 0.038).
Follow-up DEPS questionnaire was completed by 12
patients (60%) (Table 1). In the follow-up questionnaire,
2 patients reported abnormally high DEPS scores of 19
and 23. One of them had received a high DEPS score
already at the initial evaluation; baseline data was not
available for the other. The first one was a male with
type I OI and a mean usage of PAP for 4.3 hours per
day for 91% of nights. The other one was a female with
type IV OI and daily use of CPAP for 7.1 hours. Both of
these patients also reported persistent excessive day-
time sleepiness.
Altogether 10 patients replied to both baseline and
follow-up DEPS questionnaires. On average, depression
symptoms remained unaltered from baseline to follow-
up with a mean score of 9 (U = 86, p = 0.94) and did not
correlate on individual patient level (p = 0.395) (Fig. 2).
Depression symptom score changes ranged from an
increase by 6 to reduction by 15 (median; increase by 1).
The two patients, who had declined from PAP treat-
ment, reported a change of 3 and − 3.
At follow-up, ESS and DEPS values correlated posi-
tively (rs=0.829, p = 0.001) implying that the more de-
pression symptoms the patient suffered from, the more
tired they felt.
Discussion
In the present pilot study, we evaluated acceptance of
positive airway pressure (PAP) therapy for sleep apnea
in a group of OI adult patients, and how self-
experienced daytime sleepiness and depression evolved
during 1- to 4-year treatment follow-up. To the best of
our knowledge this is the first study to evaluate the use
of PAP therapy in adult OI population.
Treatment options for sleep apnea in OI
Treatment of sleep apnea includes lifestyle changes,
weight control, a night splint that brings the mandible
forward, surgery, or PAP. PAP is the leading therapy and
recommended for all patients with moderate to severe
OSA (AHI ≥15) [21, 22]. Treatment of mild OSA with
PAP was recently reported to improve the quality of life
of the patients [23]. In OI patients, a removable appli-
ance for bringing the mandible forward is often contra-
dicted as the patients frequently have a relatively
prognathic mandible and may suffer from posterior open
bite [13, 24]. Thus a splint therapy would in long term
likely accentuate the malocclusion [25]. Surgical ad-
vancement of lower jaw or both jaws to increase
pharyngeal airway space would likewise be unfeasible in
OI [26]. Weight reduction in patients with low ambula-
tory ability may also be very difficult [27]. PAP treatment
therefore is the best and nearly exquisite therapy option
for OI patients with sleep apnea.
Acceptance of PAP treatment
Compliance to PAP therapy is defined as a regular use
of the appliance more than 70% of nights for at least 4
hours/night [28, 29]. In our study, 15 out of 18 (83%) pa-
tients accepted to initiate PAP therapy. Of them, 13
stayed on PAP therapy over a mean follow-up period of
41 months. This is, by far, better PAP adherence than
previously reported in non-OI patients [28]. Nonadher-
ence to PAP, defined as nightly use of less than 4 hours,
has been observed in 46 to 83% of sleep apnea patients
in the general population [29]. Discontinuation rate of
5–50% has been documented in the general population,
most frequently occurring during the first months of use
[28]. In our OI patient group, the discontinuation rate
was 13%.
Fig. 2 Boxplot of Epworth Sleepiness Scales (ESS) and self-rating
depression (DEPS) scores at baseline and after positive airway
therapy (PAP) in adult Osteogenesis imperfecta patients with
diagnosed sleep apnea
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Effects of PAP treatment on day‐time sleepiness and
depression
Past studies have demonstrated that a third of patients
in the general population are still sleepy after effective
OSA treatment, when a success has been defined as an
AHI value below 5 [30, 31]. In our study on OI, daytime
sleepiness, as expressed by ESS, remained unaffected, on
average, with treatment.
A high prevalence of depression among OSA patients
in general population has been suggested, although the
findings are inconsistent [9, 32]. Analysis of the relation-
ship is complicated by the fact that sleep apnea and de-
pression have overlapping symptoms as well as
predisposing factors, such as obesity [33]. Certainly, poor
quality of sleep affects mood through neurotransmitter
dysfunction and/or possibly also through the impaired
immune response caused by hypoxia in OSA. On the flip
side, conflicting results of OSA treatment on reducing
depression have been reported [9, 32, 34]. In our study
among adults with OI, frequency of self-reported depres-
sive symptoms remained unaffected by sleep apnea treat-
ment. Only a few papers have previously studied
depression in adults with OI. They report, in certain OI
patient groups, greater self-reported level of depression
as compared to the general population [35, 36].
A growing interest has been directed towards the con-
cepts of listening effort and fatigue, social isolation, and
depression that are associated with hearing loss [37–39].
In individuals with OI, hearing loss is more pronounced
in mild types and becomes more severe with advancing
age [37–40]. We found more reports of severe fatigue
among those adults with mild OI type as compared to
those with severe OI type [6], a finding which might be
explained partly by fatigue caused by listening effort.
Moreover, there is some evidence that OSA further af-
fects hearing functions negatively [37].
Limitations of the study
We recognize that our study was limited by the small
study cohort and variable follow up data. Missing data
reduces the power of the analysis. A shortcoming in
assessing the effect of the PAP treatment on the subject-
ive sleepiness is that we did not have polysomnographic
data on the treatment results of all the patients. Self-
reported usage of CPAP has been estimated to include
an overestimation of 1.2 hours/day on average [41]. This
would theoretically exclude one of our patients from the
target appliance adherence. In addition, our current
findings on a small patient group with relatively low
average level of sleepiness might not be representative of
the whole population. Further longitudinal studies, with
larger study population including patients with varying
severity of OSA and symptoms, would be useful to af-
firm our findings.
Conclusions
Osteogenesis imperfecta patients suffering from ob-
structive sleep apnea accepted PAP therapy well and
showed excellent adherence to it. Nevertheless, we found
that severity of self-evaluated daytime sleepiness and de-
pression did not reduce, in general, with treatment of
OSA. In patients with severe chronic conditions or de-
formity, the complexity of background factors behind
sleepiness and possibly depression may be reflected as
unexpectedly poor subjective improvement of symptoms
by PAP therapy. Further studies with larger patient co-
horts are needed to further elucidate the role of PAP in
OI management.
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